- Medtronic, plc
- Biosense Webster, Inc.
- St. Jude Medical, Inc.
- Boston Scientific Corporation
- CONMED Corporation
- AngioDynamics, Inc.
- AtriCure, Inc.
- Smith & Nephew plc
- Olympus Corporation
(Note: The list of the major players will be updated with the latest market scenario and trends)
Recent Developments in Ablation Technologies Market:
• In January 2022- Affera, a medical technology provider, and Medtronic, a leading medical device company, entered into a formal agreement for Medtronic to acquire Affera at a purchase price of USD 925 million. Prior to this agreement, Medtronic had made strategic investments in Affera, resulting in a 3% ownership stake in the company. The acquisition is aimed at enhancing Medtronic's range of advanced cardiac ablation devices and related accessories, allowing them to offer a more comprehensive and innovative selection to their customers.
Technological advancements in healthcare sector across the region are one of the major factors expected to propel the growth of the ablation technologies market. The rise in the preference towards minimally invasive approaches over traditional treatment procedures because of the different advantages offered by these procedures, including shorter hospitalization, less pain, quicker recovery, more cosmetic incisions, lower risk of infection, reduced post-operative care, and more cosmetic incisions accelerate the market growth. The development of non-thermal and non-sclerosant endovenous ablation devices, and the increase in the prevalence of life-threatening diseases, such as chronic venous insufficiency, atrial fibrillation, and cancer, further influence the market. Additionally, technological advancements in medical devices, improvements in the medical industry, and growth in awareness about the benefits of minimally invasive procedures positively impact the ablation technology market. Furthermore, developing next-generation ablation devices with robotic navigation systems expands profitable opportunities for the market players in the forecast period. Furthermore, high costs associated with the treatment and availability of effective conventional therapies are expected to obstruct market growth. Cardiac arrhythmia, cancers, ophthalmologic and urological treatments, and ablation technology are considerably advanced. These diseases are disastrous as they have a history of severe symptoms, further obstructing market growth.